Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $1.2 billion.

  • Rxo's Cost of Revenue fell 1134.86% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 billion, marking a year-over-year increase of 2934.08%. This contributed to the annual value of $4.6 billion for FY2025, which is 2934.08% up from last year.
  • Rxo's Cost of Revenue amounted to $1.2 billion in Q4 2025, which was down 1134.86% from $1.1 billion recorded in Q3 2025.
  • Rxo's Cost of Revenue's 5-year high stood at $1.4 billion during Q4 2024, with a 5-year trough of $699.0 million in Q1 2024.
  • For the 5-year period, Rxo's Cost of Revenue averaged around $932.0 million, with its median value being $880.5 million (2022).
  • Per our database at Business Quant, Rxo's Cost of Revenue tumbled by 2566.11% in 2023 and then skyrocketed by 8263.8% in 2024.
  • Over the past 5 years, Rxo's Cost of Revenue (Quarter) stood at $1.1 billion in 2021, then fell by 19.89% to $842.0 million in 2022, then fell by 11.76% to $743.0 million in 2023, then soared by 82.64% to $1.4 billion in 2024, then decreased by 11.35% to $1.2 billion in 2025.
  • Its Cost of Revenue stands at $1.2 billion for Q4 2025, versus $1.1 billion for Q3 2025 and $1.1 billion for Q2 2025.